Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologic therapies: what and when?

Sarah L Johnston1

  • 1Department of Immunology and Immunogenetics, Southmead Hospital, Bristol, UK. sarah.johnston@nbt.nhs.uk

Journal of Clinical Pathology
|January 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: A simple case of drug-induced secondary antibody deficiency or a rare primary immune deficiency?

Frontiers in immunology·2025
Same author

Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies.

Frontiers in immunology·2021
Same author

Cell separation in kiwifruit without development of a specialised detachment zone.

BMC plant biology·2017
Same author

False interpretation of diagnostic serology tests for patients treated with pooled human immunoglobulin G infusions: a trap for the unwary.

Clinical medicine (London, England)·2015
Same author

An enzyme activity capable of endotransglycosylation of heteroxylan polysaccharides is present in plant primary cell walls.

Planta·2012
Same author

Down-regulation of POLYGALACTURONASE1 alters firmness, tensile strength and water loss in apple (Malus x domestica) fruit.

BMC plant biology·2012
Same journal

Defining biochemical, pathological and molecular factors prognostic in terms of disease control and survival in high-grade extremity soft tissue sarcoma: a scoping review.

Journal of clinical pathology·2026
Same journal

MILGDF: a multi-task, instance-level supervised model for oral squamous cell carcinoma integrating local-global attention and dynamic decision fusion.

Journal of clinical pathology·2026
Same journal

Paediatric B-lymphoblastic leukaemia with low peripheral blasts: a potential diagnostic pitfall.

Journal of clinical pathology·2026
Same journal

MRI-targeted versus systematic needle core biopsies in prostate cancer: a patient-based analysis of potential diagnostic and biologic underestimation.

Journal of clinical pathology·2026
Same journal

Basal plasmacytosis and eosinophilia for distinguishing inflammatory bowel disease from gastrointestinal tuberculosis on mucosal biopsy.

Journal of clinical pathology·2026
Same journal

Assay-dependent variability in free thyroxine (FT4): differential interference related to immunoassay design in a patient with subclinical hypothyroidism.

Journal of clinical pathology·2026
See all related articles

Biologic therapies, including monoclonal antibodies and fusion proteins, have advanced significantly. This review covers their application in immune-mediated diseases, focusing on FDA/EMA-approved molecular targets.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Major advances in understanding the immune system and disease pathogenesis over the last two decades.
  • Concurrent development of biologic therapies, such as monoclonal antibodies and fusion proteins.

Purpose of the Study:

  • To review the application of biologic therapies in immune-mediated diseases.
  • To discuss molecular targets involved in pathogenesis with US Food and Drug Administration/European Medicines Agency approval.
  • To briefly comment on biologics approved for non-immune disorders.

Main Methods:

  • Literature review focusing on immune-mediated diseases and biologic therapies.
  • Analysis of molecular targets and their role in pathogenesis.
  • Inclusion of US Food and Drug Administration/European Medicines Agency-approved treatments.

Related Experiment Videos

Main Results:

  • Biologic therapies represent a significant advancement in treating immune-mediated diseases.
  • Understanding molecular targets is crucial for effective therapeutic decisions.
  • Approved biologics offer targeted treatment options for various immune disorders.

Conclusions:

  • The clinical application of biologic therapies requires careful consideration of immune biology and specific molecular targets.
  • Biologics targeting specific pathways have transformed the management of immune-mediated diseases.
  • Further research into novel molecular targets will continue to advance biologic therapy development.